DGNOF (Diagnos) 3-1 Month Momentum %: 5.05% (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DGNOF Diagnos Inc DGNOF
22 GF Score
Price $0.33
! 6 Warning Signs
View Full Analysis

What is Diagnos 3-1 Month Momentum %?

Diagnos DGNOF +10.02% 22 3-1 Month Momentum % is 5.05% as of Aug. 27, 2026. GuruFocus rates DGNOF with a GF Score™ of 22/100. The stock has 6 warning signs investors should review. Among 669 Healthcare Providers & Services companies, Diagnos ranks better than 78.03% on this metric.

3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-27), Diagnos's 3-1 Month Momentum % is 5.05%.

The industry rank for Diagnos's 3-1 Month Momentum % or its related term are showing as below:

DGNOF's 3-1 Month Momentum % is ranked better than
78.03% of 669 companies
in the Healthcare Providers & Services industry
Industry Median: -2.17 vs DGNOF: 5.05

Diagnos  (OTCPK:DGNOF) 3-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Diagnos 3-1 Month Momentum % Related Terms

DGNOF vs VEEV, BTSG, HQY: 3-1 Month Momentum % Comparison

For the Health Information Services subindustry, Diagnos's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Diagnos 3-1 Month Momentum % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's 3-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Diagnos's 3-1 Month Momentum % falls into.


DGNOF
22GF Score
Diagnos Inc DGNOF
3-1 Month Momentum % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnos  (OTCPK:DGNOF) 3-1 Month Momentum % Calculation

3-1 Month Momentum % is calculated as following:

3-1 Month Momentum %=( Price 1-month ago / Price 3-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 3-1 Month Momentum % →
What does a 3-1 Month Momentum % of 5.05% mean?
Diagnos (DGNOF) has a 3-1 Month Momentum % of 5.05% as of Aug. 27, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Diagnos and its competitors. According to the industry distribution chart, Diagnos ranks #147 out of 669 companies in the Healthcare Providers & Services industry, placing it in the top 22%.
Is Diagnos' 3-1 Month Momentum % too high?
Diagnos' current 3-1 Month Momentum % is 5.05%. Based on the distribution chart, Diagnos ranks #147 out of 669 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnos has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Diagnos' 3-1 Month Momentum % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #147 out of 669 companies for 3-1 Month Momentum %. This places Diagnos in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Healthcare Providers & Services company?
A good 3-1 Month Momentum % depends on the Healthcare Providers & Services industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Diagnos and its competitors. Diagnos's current 3-1 Month Momentum % is 5.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Diagnos (DGNOF) has a current 3-1 Month Momentum % of 5.05%. The current 3-1 Month Momentum % is 5.05%. Diagnos' overall GF Score™ is 22/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Diagnos (DGNOF), the current 3-1 Month Momentum % is 5.05% as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Diagnos Business Description

Other Exchanges ADK:Canada
Address 7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
22GF Score

Get the complete analysis for DGNOF

3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.33
Price